Better biotherapeutic characterization for improved quality control
At the recent WCBP conference in Washington, D.C., Dr. Stuart Knowling from Antibody Analytics presented how the latest innovation in surface plasmon resonance (SPR) technology has been adopted to develop and qualify assays for monoclonal antibodies (mAbs) and other therapeutic proteins to ensure drug quality.
Sign up to view an on-demand recording and receive a free copy of our poster booklet, Better Biotherapeutic Characterization for Improved Quality Control. Enjoy!